InsidersTradesSigma
Follow the Thermo Fisher Scientific INC. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Thermo Fisher Scientific INC. has logged 518 insider filings. Market capitalisation: €228.2bn. The latest transaction was reported on 1 September 2026 (Retenue fiscale). Among the most active insiders: CASPER MARC N. All data is free.
518
Insider Decl.
n/a
Thresholds
€10,216
2 ops.
Buy Volume
€90m
163 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Thermo Fisher Scientific INC. Buy (bullish), based on 26 analysts. Average price target: US$631.42.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,060 of 29,063 companies
51.0
score / 100
Value41
Quality61
FCF yld2.8%
Earn yld2.9%
EV/EBITDA23.3x
ROE14%
Gross mgn41%
Net mgn15%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 September 2026
Declarations518 total
10.567 shares@ US$622.18Common StockSEC:0000097745-26-000163:0
12.915 shares@ US$622.18Common StockSEC:0000097745-26-000163:1
11.447 shares@ US$622.18Common StockSEC:0000097745-26-000163:2
14.97 shares@ US$622.18Common StockSEC:0000097745-26-000163:3
37.23 shares@ US$622.18Common StockSEC:0000097745-26-000166:0
44.483 shares@ US$622.18Common StockSEC:0000097745-26-000166:1
19.824 shares@ US$622.18Common StockSEC:0000097745-26-000166:2
55.12 shares@ US$622.18Common StockSEC:0000097745-26-000166:3
113.623 shares@ US$622.18Common StockSEC:0000097745-26-000166:4
87.03 shares@ US$622.18Common StockSEC:0000097745-26-000161:0
116.04 shares@ US$622.18Common StockSEC:0000097745-26-000161:1
105.403 shares@ US$622.18Common StockSEC:0000097745-26-000161:2
85.096 shares@ US$622.18Common StockSEC:0000097745-26-000161:3
724.766 shares@ US$622.18Common StockSEC:0000097745-26-000167:0
531.851 shares@ US$622.18Common StockSEC:0000097745-26-000167:1
4,133 shares@ US$614.380.0011% mcap27.6% of flowCommonSEC144:0001959173-26-006539
275 shares@ US$309.630.0000% mcap0.0% of flowCommon StockSEC:0001216055-26-000012:0
79 shares@ US$628.010.0000% mcap0.0% of flowCommon StockSEC:0001216055-26-000012:3
101 shares@ US$625.410.0000% mcap0.0% of flowCommon StockSEC:0001216055-26-000012:1
33 shares@ US$626.590.0000% mcap0.0% of flowCommon StockSEC:0001216055-26-000012:2
62 shares@ US$628.740.0000% mcap0.0% of flowCommon StockSEC:0001216055-26-000012:4
275 shares@ US$627.04780.0001% mcap0.1% of flowCommonSEC144:0001959173-26-006401
2,727 shares@ US$625.460.0007% mcap0.9% of flowCommon StockSEC:0000097745-26-000152:11
10,000 shares@ US$309.630.0013% mcap1.6% of flowCommon StockSEC:0000097745-26-000152:0
909 shares@ US$625.450.0002% mcap0.3% of flowCommon StockSEC:0000097745-26-000152:1
25 of 518 declarations
关于 Thermo Fisher Scientific INC.
赛默飞世尔科技公司（股票代码：TMO）是科学仪器、实验室耗材、诊断、生物生产和外包制药服务领域的全球领导者。该公司在美国纽约证券交易所/纳斯达克市场上市，总部位于马萨诸塞州沃尔瑟姆。实际上，赛默飞世尔是生命科学和工业科学领域最全面的“镐和铲”供应商之一：它提供工具和服务，帮助客户发现药物、测试材料、运营实验室和制造先进疗法。其定位通常被描述为大规模服务科学，其产品组合涵盖研究、临床和应用市场。（[corporate.thermofisher.com](https://corporate.thermofisher.com/us/en/index/about.html?utm_source=openai)) 该公司起源于1956年成立的Thermo Electron，几十年来通过收购和产品组合建设（包括Fisher Scientific）不断扩张，成为一个高度整合的全球平台。赛默飞世尔通过生命科学解决方案、分析仪器、专业诊断以及实验室产品和生物制药服务等主要部门报告其业务。这种结构使其能够涉足整个科学工作流程：分子生物学和测序、质谱、色谱、样品制备、实验室设备、专业诊断、常规实验室用品、合同开发和制造以及临床研究服务。（[sec.gov](https://www.sec.gov/Archives/edgar/data/97745/000009774525000101/tmo-20250628.htm?utm_source=openai)) 从竞争角度来看，赛默飞世尔受益于规模、品牌实力、深厚的客户关系和非常广泛的装机量。其旗舰品牌包括Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services、Patheon和PPD。该产品组合帮助公司在学术研究、生物制药、临床诊断和工业测试领域展开竞争，同时还提供交叉销售机会和经常性耗材收入。在地理上，赛默飞世尔拥有真正的全球足迹，通过广泛的制造、商业和服务网络为北美、欧洲和亚太地区的客户提供服务。（[ir.thermofisher.com](https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Expands-Global-Biobank-Leadership-Through-Strategic-Collaboration-with-PRECISE-SG100K-Singapore-to-Advance-Population-Scale-Proteomics/default.aspx?utm_source=openai)) 最近的发展表明其积极管理的产品组合和持续创新。在2026年第一季度，赛默飞世尔报告收入为11.01 billion美元，增长6%，并重点介绍了仪器、应用分析和细胞疗法制造领域的几款产品发布。2026年1月，该公司宣布与NVIDIA建立战略合作，以推进人工智能驱动的实验室自动化并提高工作流程性能。2026年4月，它还宣布与新加坡的PRECISE-SG100K合作，以支持人口规模的生物样本库和蛋白质组学。此外，赛默飞世尔于2026年4月签署协议，将其微生物业务出售给Astorg，这突显了管理层重塑产品组合和重新部署资本的意愿。（[ir.thermofisher.com](https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Reports-First-Quarter-2026-Results/default.aspx?utm_source=openai))
